We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Idealp-Pharma Launches ‘Hit-To-Candidate’ Services

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Idealp-Pharma is launching fully integrated drug discovery and preclinical development services combining medicinal chemistry, cheminformatics, screening, early ADMET and preclinical development capabilities to speed up partner’s and client’s small molecules programs from biological target to firstin-man use.

According to Serge Petit, PhD, President and CEO, “Being a one-stop-shop company adds significant value because the lead optimization process involves iterative cycles for incremental optimization. The main advantages of our one-stop-shop service are to have access to all the experimental data, to be able to refocus the synthesis program and then to make the best decision for the lead optimization process in accordance with our customers' specifications.”

“Idealp-Pharma manages its customers' hit discovery and validation, hit-to-lead progression and lead-to-candidate process. Our aim is to deliver chemically and biologically validated hits, accelerating lead optimization and identying IND candidate for our customers”, said Serge Petit.